PhD Damijan Knez

PhD Damijan Knez
no.: 36438 source: ARIS

researcher – active in research organisation
  damijan.knezat signffa.uni-lj.si
  • English
  • Reading: Fluent
  • Writing: Fluent
  • Speaking: Fluent
Edit
Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   
Keywords
medicinal chemistry, enzyme inhibitors, drug design, Alzheimer's disease
Bibliography Representative bibliographic units | Personal | COBISS+
source: COBISS
source: SICRIS
Evaluation (metodology)
Evaluation of bibliographic research performance indicators according to ARIS methodology
source: COBISS
source: ARIS
Points
1,110.77
A''
225.92
A'
689.95
A1/2
860.84
CI10
1,806
CImax
133
h10
25
A1
4.14
A3
0.09
Data for the last 5 years (citations for the last 10 years) on December 26, 2025; Data for score A3 calculation refer to period 2020-2024 (2022, 2023, 2024)
Data for ARIS tenders ( 21.05.2024 – Target research programmes, archive )
Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
source: WoS source: Scopus source: COBISS
Database Linked records Citations Pure citations Average pure citations
WoS 87  1,982  1,726  19.84 
Scopus 89  2,092  1,820  20.45 
Education
source: ARIS
Level of education Professional title Study subject Faculty Year
2nd cycle master's degree  B. Sc.     SI University of Ljubljana, Faculty of Pharmacy 2013 
Doctoral degree  Ph. D.   Biomedicine  SI University of Ljubljana, Faculty of Pharmacy 2017 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Employments
source: ARIS
Type of employment Research org. Research group Date of employment Position Role Title
Full time employment (100%, RD:100%)  University of Ljubljana, Faculty of Pharmacy  Chair for Pharmaceutical Chemistry  10/1/2013  Senior research associate  Researcher  Associate professor 
Research projects Legend
source: ARIS
no. Code Title Period Head
1. N1-0331  A double whammy for the NF-κB signalling pathway: development of TAK1 and IKKβ degraders against inflammation-driven diseases   1/1/2024 - 12/31/2027  PhD Izidor Sosič   1,142 
2. J1-50023  3DfluorCO - Three-dimensional fluorine-based carbonyl bioisosteres: asymmetric synthesis and validation   10/1/2023 - 9/30/2026  PhD Andrej Emanuel Cotman   1,247 
3. J1-50037  Development of CDK1-selective degraders for the treatment of T-cell malignancies   10/1/2023 - 9/30/2026  PhD Izidor Sosič   1,336 
4. N1-0277  Research of multifunctional compounds targeting neuroinflammation and cholinergic deficit in Alzheimer's disease   1/1/2023 - 12/31/2025  PhD Stanislav Gobec   1,426 
5. J1-4417  Development of novel small molecule Toll-like receptors 7 and 8 modulators for cancer immunotherapy   10/1/2022 - 9/30/2025  PhD Matej Sova   4,387 
6. J3-3071  Cathepsins B and X in breast cancer stem cells – molecular targets and relevance for antitumor therapy   10/1/2021 - 3/31/2025  PhD Ana Mitrović   2,889 
7. BI-FR/23-24-PROTEUS-002  Development of effective reactivators of organophosphate-inhibited butyrylcholinesterase   1/1/2023 - 12/31/2024  PhD Damijan Knez   277 
8. L1-3160  Development of highly concentrated protein formulations and evaluation of absorption kinetics after subcutaneous administration   10/1/2021 - 9/30/2024  PhD Iztok Grabnar   3,305 
9. J1-3018  Smart probes for ex vivo assay-based early prediction of Alzheimer disease   10/1/2021 - 9/30/2024  PhD Janez Košmrlj   2,503 
10. BI-US/22-24-004  Optimization of selective butyrylcholine esterase inhibitors as potential therapeutic agents for heroin abuse therapy   7/1/2022 - 6/30/2024  PhD Damijan Knez   277 
11. N1-0169  Kovalentni pristop k boju proti bakterijski rezistenci (Slovene)   1/1/2021 - 12/31/2023  PhD Stanislav Gobec   1,373 
12. Z1-1859  Targeted covalent inhibitors: inhibiting monoamine oxidase through non-catalytic amino-acid residues   7/1/2019 - 6/30/2021  PhD Damijan Knez   277 
13. J3-9267  Inhibition of cathepsin X activity as a novel strategy for the treatment of Parkinson's disease   7/1/2018 - 6/30/2021  PhD Anja Pišlar   3,050 
14. J1-9192  New anticancer leads for emerging cancer target potassium ion channels hEag1 and its validation in lymphoma tumors   7/1/2018 - 6/30/2021  PhD Lucija Peterlin Mašič   2,502 
15. N1-0068  Identification of non-peptidic inhibitors of the immunoproteasome using fragment based drug discovery methods   11/1/2017 - 10/31/2020  PhD Stanislav Gobec   2,100 
16. J1-8145  Dinamični vidik vezave ligandov na proteine (Slovene)   5/1/2017 - 4/30/2020  PhD Simona Golič Grdadolnik   1,988 
17. J1-8152  Inhibicija prenove celične stene Staphylococus aureus (Slovene)   5/1/2017 - 4/30/2020  PhD Dušan Turk   2,226 
18. J4-8227  Preprečevanje rezistence tumorskih celic na antiproteazno terapijo z inhibitorji katepsina X. (Slovene)   5/1/2017 - 4/30/2020  PhD Janko Kos   5,190 
19. L1-8157  Razvoj multifunkcionalnih učinkovin za zdravljenje Alzheimerjeve bolezni (Slovene)   5/1/2017 - 4/30/2020  PhD Stanislav Gobec   5,096 
20. J1-7479  Structural insight into iodine metabolism   1/1/2016 - 12/31/2018  PhD Dušan Turk   1,980 
21. L1-6745  Boj proti bakterijski rezistenci: optimizacija zaviralcev biosinteze bakterijske stene (Slovene)   7/1/2014 - 6/30/2017  PhD Stanislav Gobec   3,580 
ARIS research and infrastructure programmes Legend
source: ARIS
no. Code Title Period Head
1. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2022 - 12/31/2027 PhD Stanislav Gobec   6,035 
2. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2015 - 12/31/2021 PhD Stanislav Gobec   6,728 
3. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2009 - 12/31/2014 PhD Danijel Kikelj   6,592 
Confirmation required
Views history
Favourite